Overview
GLP-1 receptor agonist medications — including semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) — have become among the most widely prescribed drugs in the United States, used to treat type 2 diabetes and obesity. While these medications have demonstrated significant metabolic benefits, emerging research has identified a serious and potentially devastating side effect: Nonarteritic Anterior Ischemic Optic Neuropathy, or NAION.
NAION is a form of vision loss caused by insufficient blood flow to the optic nerve. It can result in sudden, permanent partial or complete blindness in one or both eyes. There is no effective treatment to restore vision once NAION has occurred.
If you or a loved one experienced sudden vision loss while taking Ozempic, Wegovy, Mounjaro, Rybelsus, or another GLP-1 medication, you may have a legal claim against the manufacturer.
The Link Between GLP-1 Drugs and NAION
A landmark study published in JAMA Ophthalmology in July 2024 by researchers at Harvard Medical School and Massachusetts Eye and Ear found that patients taking semaglutide faced a dramatically elevated risk of developing NAION compared to those taking other diabetes or weight loss medications. Specifically:
- Diabetic patients taking semaglutide were approximately four times more likely to develop NAION than those taking other diabetes medications
- Overweight or obese patients taking semaglutide for weight management were approximately seven times more likely to develop NAION than those taking other weight loss agents
- The researchers identified 194 cases of NAION among semaglutide users over the study period
The precise mechanism by which GLP-1 drugs may cause NAION is not yet fully understood, but researchers hypothesize that rapid changes in blood pressure, fluid distribution, or direct vascular effects on the optic nerve may play a role. The sudden and severe nature of NAION — and the lack of any effective treatment — makes this a potentially life-altering condition.
What Is NAION?
Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) occurs when blood flow to the front portion of the optic nerve is suddenly reduced or cut off, causing damage to nerve fibers responsible for vision. Unlike many conditions, NAION typically strikes without warning. Common presentations include:
- Sudden painless vision loss, often noticed upon waking
- Loss of a portion of the visual field, often the lower half
- Blurred or dim vision that does not improve
- Altered color perception
- The condition may affect one eye first, with risk of the second eye being affected over time
NAION is distinct from other causes of vision loss in that it is typically permanent. There is no FDA-approved treatment proven to restore vision after NAION has occurred, making prevention and early awareness critical.
Manufacturer Failures
Novo Nordisk (manufacturer of Ozempic, Wegovy, and Rybelsus) and Eli Lilly (manufacturer of Mounjaro) have a legal obligation to warn patients and physicians about known risks associated with their products. Plaintiffs in GLP-1 NAION litigation allege that these manufacturers:
- Failed to adequately investigate and disclose the risk of NAION in clinical trials and post-market surveillance
- Did not include adequate NAION risk warnings in prescribing information or patient labeling
- Aggressively marketed these medications to broader patient populations without disclosing the emerging evidence of optic nerve risk
Who May Have a Claim
You may have a viable NAION lawsuit if:
- You were prescribed Ozempic, Wegovy, Mounjaro, Rybelsus, or another GLP-1 receptor agonist
- You were diagnosed with NAION or experienced sudden unexplained vision loss
- Your vision loss occurred during or after your use of the medication
Given that NAION causes permanent vision impairment, damages in these cases can be significant, encompassing medical costs, lost earning capacity, and pain and suffering. Statute of limitations deadlines vary by state — contact us promptly to preserve your rights.
Contact Triten Law
Triten Law is actively reviewing NAION claims arising from GLP-1 medications. Our attorneys have deep experience in pharmaceutical mass tort litigation and will evaluate your case at no cost and with no obligation. Contact us today for a free, confidential consultation.